Navigation Links
Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
Date:5/5/2009

SAN DIEGO, May 5 /PRNewswire/ -- - Evoke Pharma, Inc., a privately-held specialty pharmaceutical company, announced today that it has initiated a Phase 2b clinical trial to evaluate EVK-001 for the treatment of adults with symptoms of diabetic gastroparesis. Gastroparesis is a syndrome characterized by delayed emptying of the stomach into the intestine following a meal in the absence of mechanical obstruction. Diabetes is an important cause of gastroparesis, but other identified causes include previous abdominal surgery, neurologic conditions, and infection. Symptoms associated with gastroparesis include: fullness after eating a small amount of food, nausea, vomiting, and bloating. In addition to diminished quality of life for all sufferers, gastroparesis symptoms increase a diabetic patient's risk of life-threatening complications from malnutrition and erratic blood sugars.

The Metoclopramide Intranasal Trial (MINT) is expected to enroll approximately 225 adult patients with diabetic gastroparesis at more than 25 clinical sites in the United States. The randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of two doses of EVK-001 over four weeks. The severity of symptoms associated with diabetic gastroparesis and the impact of gastroparesis on quality of life will be evaluated before and after EVK-001 administration.

EVK-001 is a proprietary formulation of metoclopramide that has been optimized for intranasal delivery and tolerability. Unlike tablet formulations, EVK-001 is designed to deliver a systemic dose of metoclopramide that does not depend on absorption from the gastrointestinal (GI) tract.

"Given the significant clinical need and the limited treatments available, we recognize the importance of continuing to work closely with the Food and Drug Administration (FDA) to bring the product to the market as soon as possible," states Dave Gonyer, R.Ph., Chief Executive Off
'/>"/>

SOURCE Evoke Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
2. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
3. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
4. China Biopharma, Inc. Announces New Plan of Operation
5. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
6. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
7. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
8. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
9. Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
10. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
11. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues, today ... results will be released on Thursday, August 7, 2014, ... and live webcast at 4:30 p.m. ET that afternoon. ...
(Date:7/31/2014)... July 31, 2014 Boston’s Adult Stem ... flush with innovative adult stem cell biotechnologies. Currently ... and has three additional patent applications currently under examination ... patented inventions address two of the most vexing problems ... Adult stem cells are difficult to identify; and ...
(Date:7/30/2014)... and PARIS , July 30, 2014 ... SAN and NYSE: SNY) today announced that the Companies ... (FDA) rare pediatric disease priority review voucher in connection ...  The priority review voucher entitles the holder to designate ... expedited 6-month review from the filing date instead of ...
(Date:7/30/2014)... FRANCISCO , July 30, 2014 ... Congress evaluated the safety and efficacy of CSL ... rejection following kidney transplants in highly sensitized patients. ... inhibitor of the complement system. The ... in significant increases in the levels of complement ...
Breaking Biology Technology:BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... & Burling represented AstraZeneca in its $1.26 billion ... will pay $32 per share for all of ... (Logo: http://photos.prnewswire.com/prnh/20120423/CL92331LOGO  ) AstraZeneca ... primary focus on the discovery, development and commercialization ...
...  Melanie Pita, J.D., will offer her expert perspective ... hospitals as she presents "EHRs: Meaningful Use & ... Conference, being held  April 24-26, 2012, at the ... During the presentation, Pita, who serves ...
... Inc., a leading innovator of new life science tools, today ... of its innovative portable PCR system. The F1-12 system is ... high speed and sensitivity in a fully portable format. ... Standard Fast" speed levels delivering 30-cycle PCR amplification within ...
Cached Biology Technology:Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences 2Prognosis HIS Executive Slated To Offer EHR Advice At Illinois Rural Health Association Conference 2Ahram Biosystems Announces Launch of the New Economy Model F1-12 of Its Palm PCR Series 2
(Date:7/30/2014)... David L. Kaplan, Ph.D., will head the brand-new, web-only ... editor-in-chief. With the first issue slated for publication in ... in the rapidly burgeoning field of biomaterials, the study ... living or biological systems. , "This new journal is ... field of biomaterials over the past decade and the ...
(Date:7/30/2014)... distance between two points is a straight line, and ... taking the familiar axiom to heart. , Though ... intense, with each racing for the chance to fertilize ... form cooperative groups that allow them to take a ... study, conducted by Heidi Fisher, a post-doctoral student working ...
(Date:7/30/2014)... the University of Helsinki and the Universitat Autnoma de ... morphological changes which have taken millions of years to ... development of mice teeth, induced in the laboratory, scientists ... those observed in the fossil registry of rodent species ... , To modify the development of their teeth, the ...
Breaking Biology News(10 mins):ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2When cooperation counts 2When cooperation counts 3Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2
... This news release is available in German . ... bees are dying and insect diversity is dwindling. Only recently, both ... decline, which jeopardises food security. The (lack of) pollination has thus ... habitats, and organic farming. ETH-Zurich researchers from the group headed ...
... CAMBRIDGE, Mass. , June 5, 2013  Emotient, the ... leading eye tracking and biometric software platform company, today ... and Yale University are the first customers of a ... analysis, eye tracking, EEG and GSR technologies. The combined ...
... new study finds that utilities aren,t rewarded for adopting ... make energy efficiency as attractive as renewables. The ... Environmental Law , examines key differences between energy efficiency ... professor at Oregon State University, outlines ways to increase ...
Cached Biology News:Pollination merely 1 production factor 2Pollination merely 1 production factor 3Pollination merely 1 production factor 4Emotient and iMotions Partner to Offer Unique Integrated Facial Expression Recognition, Bio Sensor and Eye Tracking Solution for Usability, Gaming, Market and Academic/ Scientific Research 2Emotient and iMotions Partner to Offer Unique Integrated Facial Expression Recognition, Bio Sensor and Eye Tracking Solution for Usability, Gaming, Market and Academic/ Scientific Research 3Emotient and iMotions Partner to Offer Unique Integrated Facial Expression Recognition, Bio Sensor and Eye Tracking Solution for Usability, Gaming, Market and Academic/ Scientific Research 4Study finds disincentives to energy efficiency can be fixed 2
... Gasket slide kit (1x 22K gasket/slide) G2534-60003 ... or Gasket slide kit (2x 11K ... slides offered in either 11K or 22K microarray feature ... gaskets are carefully fabricated and batch tested to ensure ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... locking design in ice/water bath This ... number, created to easily match Cornings ... yet, please order under the old ... service for assistance. ID clarifier: rack ...
... Microarray Kit (V2), 2 x 11K ... expression of many thousands of yeast ... important biological processes. Each microarray contains ... ORFs from the S288C strain of ...
Biology Products: